Risk profile
The probability of developing lung cancer, as determined by laboratory tests and spiral CT
Detection of early-stage lung cancers via tumor DNA in blood
Identifying germline risk mutations for early-onset and familial NSCLC
In-vivo and in-vitro diagnostics to improve lung cancer care
Dr. Nair is developing a blood test to help determine whether a pulmonary nodule seen on a PET-scan imaging screen is cancerous. The goal of this test, which will make use of circulating molecular biomarkers, is to accurately determine which patients are most likely to have lung cancer and, therefore, should have biopsies or surgery.
Developing new non-invasive methods for the diagnosis of lung cancer
Dr. Hassanein is using 164 proteins found only in lung cancer patients to develop a method to test the patient’s blood for its own antibodies to these proteins. His goal is to use these proteins as biomarkers in a blood test that will find lung cancer in its earliest, most treatable stage.
Biomarkers of pre-malignant disease progression for lung cancer detection
Identification of biomarkers for the detection of small cell lung cancer
Dr. Wistuba and his colleague Dr. Humam Kadara are identifying biomarkers that could ultimately lead to the fist test to detect small cell lung cancer in its earliest and most treatable stages.